Abstract
Objective To evaluate the The function of Alprostadil jointly for Telm isartan on High Sensitivity CRP and Cys C in patients with early diabetic nephropathy ( DN ).Methods Seventy-one patients with early DN were randomly assigned to the pure Alprostadil group(n=24)treated on Aiprostadi or the Telmisartan group(n=23)treated on telmisartan or the co-contractor group ( n=24 ) treated on Aiprostadi and Telmisartan.for 12 weeks. Changes before and after treatment in levels of blood pressure, serHm lipids, plasma glucose,HbAlc, urine albumin excretion rate ( UAER ), hsCRP and Cys-C were observed and compared between the three groups. Results The three groups showed similar levels of the indexes at baseline(P > 0.05). After 12 weeks of treatment, UAER, hsCRP, Cys C were significantly improved in three groups (P < 0.01). The combination group showed greater improvement in UAER, hsCRP and Cys C(P < 0.05)compared with the another controls. Conclusion Use of Alprostadil and telmisartan in the treatment of earlv diabetic nephr-opathy can decrease the levels of hsCRP, Cys C and microaibuminuria, And the long-term maintenance urine protein in the low level, is advantageous to the postponement even prevents diabetes nephropathy the occurrence and the development. Key words: Early diabetic nephropathy; Alprostadil; Telmisartan; High sensitivity C-reactive protein; Cystatin C
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
